MyeloMATCH MM1YA-S01 (Acute Myeloid Leukemia) - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to compare different experimental drug regimens to the usual treatment (cytarabine and daunorubicin) for acute myeloid leukemia (AML). We want to find out which options have the best outcomes. The different drug combinations we will be testing against the usual treatment are:
- daunorubicin and cytarabine liposome
- cytarabine and daunorubicin with venetoclax
- azacitidine and venetoclax
- daunorubicin and cytarabine liposome with venetoclax
¿Cuál es la Condición que se está estudiando?
Leucemia mieloide aguda (AML)
¿Quién puede participar en el Estudio?
Adultos de 18 a 59 años que:
- Are newly diagnosed with AML that is classified as high-risk (adverse) per ELN 2017 criteria
- Have not started treatment yet for AML
- Do not have acute promyelocytic leukemia
- Do not have favorable or intermediate risk disease
- Do not have any FLT3 mutations
For more information about this study, please contact the study team at marty.c.cauley@duke.edu.
Grupo etario
Adultos
¿Qué Implica?
If you choose to join this study, you will get a random assignment (fair, equal chance) to 1 of 5 groups:
- Group 1: If you are in this group, you will get the usual drugs used to treat this type of cancer (cytarabine and daunorubicin).
- Group 2: If you are in this group, you will get the usual treatment drugs (cytarabine and daunorubicin) plus venetoclax.
- Group 3: If you are in this group, you will get azacitidine and venetoclax.
- Group 4: If you are in this group, you will get daunorubicin and cytarabine liposome.
- Group 5: If you are in this group, you will get daunorubicin, cytarabine liposome, and venetoclax.
Detalles del Estudio
Título Completo
MyeloMATCH MM1YA-S01: A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial
Investigador Principal
Especialista en oncología hematológica
Número de Protocolo
IRB:
PRO00116098
NCT:
NCT05554406
Fase
Phase
II
ClinicalTrials.gov
View on ClinicalTrials.gov
Estado de inscripción
Abierto para inscripción